GlycoMimetics, Inc. (GLYC)
GLYC moved a median of +0.53% 30 minutes after news, and -0.07% by the close. How GLYC actually reacts to news — the realized, point-in-time move the market made, measured across 144 labeled events over the last three years with zero look-ahead.
GLYC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 119 |
| 30-min | +0.53% | 54% | 119 |
| 60-min | 0.00% | 50% | 119 |
| to close | -0.07% | 47% | 119 |
| Middle 50% of GLYC reactions | -1.54% to +2.17% |
|---|---|
| Median reaction (30-min) | +0.53% |
| Measured reactions | 144 |
Half of all GlycoMimetics, Inc. news events land between -1.54% and +2.17% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GLYC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | +0.66% | 60% | -1.78% |
| Coverage initiations | 55 | 0.00% | 47% | -0.60% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how GLYC ranks against every other measured name →
That’s how GLYC usually reacts — get an email when it moves on news →Email me when GLYC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GLYC's baseline. Nothing else.
Recent GLYC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K GLYCOMIMETICS INC For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K GLYCOMIMETICS INC For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | -7.05% | |
| GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals | Press release | Business Wire | -2.54% | -7.05% | |
| Form 8-K GLYCOMIMETICS INC For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | -1.22% | |
| Form EFFECT GLYCOMIMETICS INC | SEC filing · Form EFFECT | SEC EDGAR | +2.89% | +7.76% | |
| Form 10-Q GLYCOMIMETICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.89% | +7.76% | |
| Form S-4/A GLYCOMIMETICS INC | SEC filing · Form S-4 | SEC EDGAR | +1.22% | +3.97% | |
| Form 8-K GLYCOMIMETICS INC For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -2.61% | -7.99% | |
| Form S-4/A GLYCOMIMETICS INC | SEC filing · Form S-4 | SEC EDGAR | -2.61% | -7.99% | |
| Form S-4/A GLYCOMIMETICS INC | SEC filing · Form S-4 | SEC EDGAR | +0.11% | +0.00% | |
| Form 8-K GLYCOMIMETICS INC For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | +9.87% | |
| Form S-4 GLYCOMIMETICS INC | SEC filing · Form S-4 | SEC EDGAR | -3.90% | -1.36% | |
| Form 8-K GLYCOMIMETICS INC For: Feb 14 | SEC filing · Form 8-K | SEC EDGAR | -2.88% | +2.25% | |
| Form 10-K GLYCOMIMETICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K GLYCOMIMETICS INC For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +3.62% | +11.49% | |
| Form 8-K GLYCOMIMETICS INC For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -8.29% | -2.41% | |
| Form DEFA14A GLYCOMIMETICS INC | SEC filing · Form DEFA14A | SEC EDGAR | -8.29% | -2.41% | |
| Form 8-K GLYCOMIMETICS INC For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -3.12% | -8.94% | |
| Form 10-Q GLYCOMIMETICS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.42% | +4.69% | |
| Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 | Press release | PR Newswire | -3.62% | -5.29% | |
| Form 8-K GLYCOMIMETICS INC For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +5.00% | +8.53% | |
| Form DEFA14A GLYCOMIMETICS INC | SEC filing · Form DEFA14A | SEC EDGAR | +5.00% | +8.53% | |
| GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting | Press release | Business Wire | -2.66% | -0.92% | |
| Form 8-K GLYCOMIMETICS INC For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | -12.77% | +28.24% | |
| Form DEFA14A GLYCOMIMETICS INC | SEC filing · Form DEFA14A | SEC EDGAR | -12.77% | +28.24% | |
| GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders | Press release | Business Wire | -12.77% | +28.24% | |
| GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint | Press release | Business Wire | -12.77% | +28.24% | |
| GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma | Press release | Business Wire | -12.77% | +28.24% | |
| Form 10-Q GLYCOMIMETICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.78% | +0.00% | |
| Form 8-K GLYCOMIMETICS INC For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +1.96% | +1.96% | |
| GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan | Press release | Business Wire | +0.28% | -4.20% | |
| Form 8-K GLYCOMIMETICS INC For: Jun 21 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | +15.35% | |
| Form 8-K GLYCOMIMETICS INC For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -3.27% | |
| Form 8-K GLYCOMIMETICS INC For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -0.07% | |
| GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | Press release | Business Wire | -2.63% | -2.03% | |
| GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 | Press release | Business Wire | +2.88% | +5.38% | |
| Form 10-Q GLYCOMIMETICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.39% | -4.79% | |
| Form 8-K GLYCOMIMETICS INC For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -2.30% | -7.46% | |
| GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | Press release | Business Wire | -2.52% | -10.78% | |
| Form 8-K GLYCOMIMETICS INC For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +2.38% | |
| GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 | Press release | Business Wire | +0.00% | -5.00% | |
| Form ARS GLYCOMIMETICS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.63% | -0.65% | |
| Form DEF 14A GLYCOMIMETICS INC For: May 01 | SEC filing · Form DEF | SEC EDGAR | -1.63% | -0.65% | |
| Form 10-K GLYCOMIMETICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.72% | +9.28% | |
| Form 8-K GLYCOMIMETICS INC For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +1.72% | +9.28% | |
| Form S-8 GLYCOMIMETICS INC | SEC filing · Form S-8 | SEC EDGAR | -0.96% | -3.23% | |
| GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 | Press release | Business Wire | +1.72% | +9.28% | |
| Form PRE 14A GLYCOMIMETICS INC For: May 01 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -5.05% | |
| GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 | Press release | Business Wire | +1.06% | -2.30% | |
| Form 8-K GLYCOMIMETICS INC For: Mar 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GLYC section they belong to.
Where else GLYC is measured.
GLYC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
| Mustang Bio, Inc. (MBIO) | 144 | -0.46% | 41% |
| Patterson Companies, Inc. (PDCO) | 144 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GlycoMimetics, Inc.'s median reaction calculated?
Every labeled GLYC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 144 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of GLYC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GLYC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.